Anti-regulatory T cells.
Our initial understanding of immune-regulatory cells was based on the discovery of suppressor cells that assure peripheral T-cell tolerance and promote immune homeostasis. Research has particularly focused on the importance of regulatory T cells (Tregs) for immune modulation, e.g. directing host responses to tumours or inhibiting autoimmunity development. However, recent studies report the discovery of self-reactive pro-inflammatory T cells-termed anti-regulatory T cells (anti-Tregs)-that target immune-suppressive cells. Thus, regulatory cells can now be defined as both cells that suppress immune reactions as well as effector cells that counteract the effects of suppressor cells and support immune reactions. Self-reactive anti-Tregs have been described that specifically recognize human leukocyte antigen-restricted epitopes derived from proteins that are normally expressed by regulatory immune cells, including indoleamine 2,3-dioxygenase (IDO), tryptophan 2,6-dioxygenase (TDO), programmed death-ligand 1 (PD-L1), and forkhead box P3 (Foxp3). These proteins are highly expressed in professional antigen-presenting cells under various physiological conditions, such as inflammation and stress. Therefore, self-reactive T cells that recognize such targets may be activated due to the strong activation signal given by their cognate targets. The current review describes the existing knowledge regarding these self-reactive anti-Tregs, providing examples of antigen-specific anti-Tregs and discussing their possible roles in immune homeostasis and their potential future clinical applications.
Department of Hematology, Center for Cancer Immune Therapy (CCIT), Copenhagen University Hospital, Herlev, 2730, Herlev, Denmark. mads.hald.andersen@regionh.dk.|Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark. mads.hald.andersen@regionh.dk.
Mads Hald
MH
Andersen
D000818:Animals; D015551:Autoimmunity; D015415:Biomarkers; D016207:Cytokines / Q000378:metabolism; D000939:Epitopes / Q000276:immunology; D006801:Humans; D056747:Immunomodulation; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase / Q000276:immunology / Q000378:metabolism; D007249:Inflammation / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D018836:Inflammation Mediators / Q000378:metabolism; D009369:Neoplasms / Q000276:immunology / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D015398:Signal Transduction; D016176:T-Lymphocyte Subsets / Q000276:immunology* / Q000378:metabolism; D050378:T-Lymphocytes, Regulatory / Q000276:immunology* / Q000378:metabolism; D014612:Vaccines / Q000276:immunology
D015415:Biomarkers; D016207:Cytokines; D000939:Epitopes; D050503:Indoleamine-Pyrrole 2,3,-Dioxygenase; D018836:Inflammation Mediators; D014612:Vaccines
Anti-Tregs; Anti-regulatory T cells; Foxp3; IDO; Immune regulation; PD-L1; Tregs
Oncoimmunology. 2012 Oct 1;1(7):1211-1212
23170283
Cancer Res. 2011 Mar 15;71(6):2038-44
21406395
Immunity. 2005 May;22(5):633-42
15894280
Oncoimmunology. 2015 Jan 30;4(1):e968480
25949861
J Natl Cancer Inst. 2015 Jun 10;107(9):null
26063792
Atherosclerosis. 2010 Mar;209(1):74-80
19765709
Nat Med. 2003 Oct;9(10):1269-74
14502282
J Exp Med. 2003 Dec 15;198(12):1875-86
14676299
Leukemia. 2012 Feb;26(2):199-213
21852787
Leukemia. 2013 Nov;27(11):2251-3
23660624
Cancer Res. 2009 Mar 1;69(5):2000-9
19244125
PLoS One. 2009 Sep 07;4(9):e6910
19738905
J Clin Invest. 2007 May;117(5):1147-54
17476344
J Clin Invest. 2003 Feb;111(3):363-70
12569162
J Immunol. 2013 Apr 1;190(7):3783-97
23440412
Cancer Immunol Immunother. 2012 Aug;61(8):1289-97
22388712
N Engl J Med. 2012 Jun 28;366(26):2443-54
22658127
J Immunother. 2015 Sep;38(7):285-91
26261892
Leukemia. 2013 Dec;27(12):2332-40
23812418
Oncoimmunology. 2016 Jul 01;5(8):e1202391
27622072
Nat Med. 2004 Sep;10(9):942-9
15322536
Cancer Res. 2006 Jun 1;66(11):5716-22
16740709
Nature. 2007 Nov 22;450(7169):566-9
18033300
Lung Cancer. 2009 Jul;65(1):91-7
19054590
J Exp Med. 2005 Sep 5;202(5):673-85
16147978
Cancer Res. 2013 Mar 15;73(6):1764-76
23328583
Science. 2005 Nov 4;310(5749):850-5
16272121
Curr Infect Dis Rep. 2005 May;7(3):227-234
15847726
J Exp Med. 2005 Sep 19;202(6):771-81
16172257
Leukemia. 2009 Feb;23(2):375-82
18830259
Leukemia. 2013 Feb;27(2):464-72
22828443
Oncoimmunology. 2013 Apr 1;2(4):e23991
23734334
Leukemia. 2012 May;26(5):1053-63
22015774
J Transl Med. 2014 Sep 24;12:267
25245466
Cancer Res. 2007 Jan 1;67(1):371-80
17210720
Oncoimmunology. 2012 Nov 1;1(8):1290-1296
23243592
Leukemia. 2014 May;28(5):993-1000
24153012
Immunology. 2008 Feb;123(2):263-71
17725606
J Exp Med. 1993 Sep 1;178(3):909-16
7688792
PLoS One. 2012;7(4):e34568
22539948
Oncoimmunology. 2013 Oct 1;2(10):e26247
24498544
Leukemia. 2005 Dec;19(12):2273-80
16304575
Leukemia. 2012 Mar;26(3):424-32
21904385
J Exp Med. 2008 Sep 1;205(9):1983-91
18725525
J Exp Med. 2002 Aug 19;196(4):459-68
12186838
Blood Cancer J. 2014 Jul 18;4:e230
25036801
Blood. 2006 Oct 1;108(7):2265-74
16741252
Immunity. 2015 May 19;42(5):929-41
25992863
Leukemia. 2014 Jun;28(6):1280-8
24270737
Blood. 2011 Feb 17;117(7):2200-10
21079151
Immunol Rev. 2008 Jun;223:371-90
18613848
Proc Natl Acad Sci U S A. 2008 May 6;105(18):6690-5
18436652
Nat Rev Immunol. 2005 Aug;5(8):641-54
16056256
Proc Natl Acad Sci U S A. 2008 Aug 19;105(33):11903-8
18695219
Leukemia. 2014 Jan;28(1):236-8
24091833
J Clin Invest. 2009 Aug;119(8):2245-56
19662679
Blood. 2013 Aug 1;122(5):749-58
23733335
Oncogene. 2008 Jun 26;27(28):3889-900
18317452
Immunol Rev. 2006 Aug;212:28-50
16903904
Cancer Discov. 2012 Aug;2(8):722-35
22822050
Springer Semin Immunopathol. 2006 Aug;28(1):1-2
16896608
J Am Chem Soc. 2007 Dec 19;129(50):15690-701
18027945
N Engl J Med. 2012 Jun 28;366(26):2455-65
22658128
Clin Cancer Res. 2014 Jan 1;20(1):221-32
24218513
Blood. 2013 Jan 31;121(5):734-44
23223433